Work

A phase Ib/II study of pacritinib, an interleukin 1 receptor associated kinase 1 (IRAK1) inhibitor, in patients (pts) with solid tumors harboring the 1q21.3 copy number amplification (CNA).

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.23_suppl.43

Authors: Joline Si Jing Lim, Mei Yee Aau, Joe Yeong, Boon Cher Goh, Wei Peng Yong, Ross A. Soo, Andrea Wong, David Shao Peng Tan, Cheng Ean Chee, Raghav Sundar, Anand Devaprasath Jeyasekharan, Calista Wong, Polly Leilei Chen, Hai Yan Liu, Qiang Yu, Wai Leong Tam, Soo-Chin Lee

Institutions: National University Cancer Institute, Singapore, Genome Institute of Singapore, Agency for Science, Technology and Research, Institute of Molecular and Cell Biology, Cancer Science Institute of Singapore, National University of Singapore

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Medical Research Council

OpenAlex ID: W4401514389

Cites:

Cited by: 1

Related to: 10